scorecardresearch
Add as a preferred source on Google
Saturday, January 3, 2026
TopicCDSCO

Topic: CDSCO

Use nimesulide only after exhausting first-line options—expert panel under drug regulator CDSCO

Last year, an ICMR panel even considered recommending all-India ban on popular painkiller amid concerns it could cause liver damage, which could turn life-threatening in some cases.

As CDSCO lifts suspension on eye drops designed to replace reading glasses, makers eye June launch

Doctors caution that the drug should be used only under strong and regular supervision of an ophthalmologist.

No local clinical trial waiver despite change in rules, drugmakers knock on health ministry’s door

Drug regulator through executive order issued last August paved way for direct launch of certain categories of drugs approved in select countries by means of local clinical trials waiver.

Antibiotics launched in India will soon need CDSCO nod as drug resistance emerges as silent killer

In 2019, bacterial antimicrobial resistance killed between 3 lakh and 10.4 lakh people in India, according to a Lancet report.

Why a govt-appointed panel has recommended a complete ban on popular painkiller nimesulide

First launched in Italy in 1985, Nimesulide is available in India under brand names like Nimuwin, Nimutab, Nimopen, Nisulid, Nimdase, Nodard Plus, Nicip, Nimcap, Nicip-P and Nimupain.

Govt says no plan to ban heartburn drug ranitidine, carcinogenic impurities within safe limits

In 2019, evidence showed that an impurity in drug degrades over time to form probable carcinogenic compound. Ranitidine is sold as heartburn medicine under names Rantac, Aciloc & Zinetac.

Drug regulator considers making central nod mandatory for all antibiotics in India, even existing ones

This new proposal, being considered by CDSCO, comes in response to concerns over antimicrobial resistance emerging as a massive public health challenge across the globe, including in India.

India has a substandard, fake drugs problem. Lack of recall law, scrutiny is making matters worse

Underlining need for more accountability, experts also stress that govt data does not include fixed dose combination drugs, which account for over 40% of drugs sold in India.

Eye drop’s claim to replace glasses cost it the launch & sale nod. The controversy & safety concerns

Regulatory approval to Entod Pharma for PresVu, meant to treat presbyopia, was revoked as the firm marketed it as a 'replacement for reading glasses' & due to possible health risks.

‘Unauthorised promotion’, risk of unsafe use: Why CDSCO revoked nod for eye drops to replace glasses

Drugs Controller General of India, who heads CDSCO, says Entod pharma failed to reply satisfactorily to queries raised. Entod to challenge suspension of approval.

On Camera

How Gen-Z is changing the violent extremist landscape online

The evolving extremist threat now hinges on young people online, demanding new strategies beyond traditional counter-terror models.

India’s urban co-op banks are turning the page—crisis to cautious revival, one metric at a time

With bad loans shrinking & capital buffers stronger, urban co-op banks’ new umbrella body NUCFDC is now prioritising rollout of digital transformation.

Greece looking at TATA’s WhAP infantry combat vehicle for army procurement

If deal goes through, Greece will be 2nd foreign country to procure vehicle. Morocco was first; TATA Group has set up manufacturing unit there with minimum 30 percent indigenous content.

A year-end Mea Culpa in National Interest—The Army-Islam combo doesn’t kill democracy

Many of you might think I got something so wrong in National Interest pieces written this year. I might disagree! But some deserve a Mea Culpa. I’d deal with the most recent this week.